AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12740277 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (no BPS)
Number of subjects: 43
Study 11049203 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium selenite 200 microg/d
Number of subjects: 0
Study 11049203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9291243 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide (INTEGRILIN)
Number of subjects: 0
Study 9291243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8450730 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthpiece-breathing valve apparatus (MP)
Number of subjects: 17
Study 8450730 — intervention group
Group type: COMPARATOR
Intervention: Respiratory face mask (MASK)
Number of subjects: 17
Study 8450730 — intervention group
Group type: COMPARATOR
Intervention: Running without respiratory apparatus (NOR)
Number of subjects: 17
Study 3468598 — intervention group
Group type: EXPERIMENTAL
Intervention: Effervescent vitamin C preparations
Number of subjects: 0
Study 3468598 — intervention group
Group type: COMPARATOR
Intervention: Effervescent calcium preparations
Number of subjects: 0
Study 3468598 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C preparations (excess consumption)
Number of subjects: 0
Study 3468598 — intervention group
Group type: COMPARATOR
Intervention: No mechanical cleaning
Number of subjects: 0
Study 31883933 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided supraclavicular brachial plexus block (BPB)
Number of subjects: 80
Study 31883933 — intervention group
Group type: COMPARATOR
Intervention: No regional anesthesia (control group)
Number of subjects: 80
Study 29943185 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-guided transurethral ultrasound ablation (TULSA)
Number of subjects: 29
Study 29943185 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed thermal ablation volume (DTAV, 240 cumulative equivalent minutes at 43°C)
Number of subjects: 29
Study 29943185 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate post-treatment non-perfused volume (NPV)
Number of subjects: 29
Study 27928711 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasonography (LUS) with bioimpedance-guided protocol
Number of subjects: 250
Study 27928711 — intervention group
Group type: COMPARATOR
Intervention: Clinical assessment (control)
Number of subjects: 250
Study 25936187 — intervention group
Group type: EXPERIMENTAL
Intervention: High negative pressure drainage (60 kPa)
Number of subjects: 74
Study 25936187 — intervention group
Group type: COMPARATOR
Intervention: Low negative pressure drainage (30 kPa)
Number of subjects: 74
Study 25936187 — intervention group
Group type: EXPERIMENTAL
Intervention: High negative pressure drainage (60 kPa) after 3 days
Number of subjects: 74
Study 25936187 — intervention group
Group type: COMPARATOR
Intervention: Low negative pressure drainage (30 kPa) after 3 days
Number of subjects: 74
Study 24084627 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow reversal
Number of subjects: 40
Study 24084627 — intervention group
Group type: COMPARATOR
Intervention: Filter protection
Number of subjects: 40
Study 24084627 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 21747837 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral zinc sulfate (10 mg/kg/day for 45 days)
Number of subjects: 100
Study 21747837 — intervention group
Group type: COMPARATOR
Intervention: Systemic meglumine antimoniate (20 mg/kg/day intramuscularly for 20 days)
Number of subjects: 100
Study 19151786 — intervention group
Group type: EXPERIMENTAL
Intervention: Haematopoietic cell transplantation (HCT)
Number of subjects: 138
Study 19151786 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (CT)
Number of subjects: 138
Study 19151786 — intervention group
Group type: EXPERIMENTAL
Intervention: HCT
Number of subjects: 138
Study 19151786 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 138
Study 17250728 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of mirtazapine 4.5 mg and ibuprofen 400 mg
Number of subjects: 93
Study 17250728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 17250728 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 93
Study 17250728 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine 4.5 mg
Number of subjects: 93
Study 15899956 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment 25.0 microg/kg.d
Number of subjects: 66
Study 15899956 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment 12.5 microg/kg.d
Number of subjects: 66
Study 15899956 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 66
Study 12575233 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (two 5-minute cycles of ischemia followed by 5-minute reperfusion)
Number of subjects: 16
Study 12575233 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 16
Study 12575233 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (Group I)
Number of subjects: 16
Study 10321443 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide 1.25 mg daily
Number of subjects: 19
Study 10321443 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-salt diet (<100 mmol/day)
Number of subjects: 19
Study 10321443 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of indapamide and low-salt diet
Number of subjects: 19
Study 10321443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 7624262 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg
Number of subjects: 12
Study 7624262 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg
Number of subjects: 12
Study 7624262 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg
Number of subjects: 12
Study 7624262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2197755 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary treatment for hyperlipidemia
Number of subjects: 0
Study 2197755 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment for hyperlipidemia
Number of subjects: 0
Study 2197755 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapies for hyperlipidemia
Number of subjects: 0
Study 403549 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana (500 mg cigarette containing 2.1% delta9-THC)
Number of subjects: 40
Study 403549 — intervention group
Group type: COMPARATOR
Intervention: Placebo cigarette
Number of subjects: 40
Study 403549 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana (second phase)
Number of subjects: 40
Study 403549 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana (group M-P)
Number of subjects: 40
Study 31702120 — intervention group
Group type: EXPERIMENTAL
Intervention: ACBMNC infusion (5 × 10^7 cells/kg)
Number of subjects: 31
Study 31702120 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 31
Study 29121359 — intervention group
Group type: EXPERIMENTAL
Intervention: 577‐nm yellow laser (YL‐577)
Number of subjects: 92
Study 29121359 — intervention group
Group type: COMPARATOR
Intervention: 532‐nm green laser (GL‐532)
Number of subjects: 92
Study 25933707 — intervention group
Group type: EXPERIMENTAL
Intervention: ProRoot MTA
Number of subjects: 46
Study 25933707 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocem
Number of subjects: 46
Study 25933707 — intervention group
Group type: COMPARATOR
Intervention: Cavity type (class I, II, III vs class V)
Number of subjects: 46
Study 24069775 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened postpartum course of magnesium sulphate (two doses of intramuscular magnesium sulphate given four hours apart)
Number of subjects: 98
Study 24069775 — intervention group
Group type: COMPARATOR
Intervention: Standard Pritchard regimen of magnesium sulphate
Number of subjects: 98
Study 24069775 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened postpartum course of magnesium sulphate
Number of subjects: 98
Study 21599928 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine
Number of subjects: 0
Study 21599928 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine
Number of subjects: 0
Study 21599928 — intervention group
Group type: COMPARATOR
Intervention: Solifenacin
Number of subjects: 0
Study 19891687 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05% foam applied twice daily for up to 2 weeks on psoriatic skin
Number of subjects: 40
Study 19891687 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05% foam applied once daily for up to 4 weeks on psoriatic skin
Number of subjects: 40
Study 19891687 — intervention group
Group type: COMPARATOR
Intervention: Clobetasol propionate 0.05% foam applied once daily for 4 weeks on healthy skin
Number of subjects: 40
Study 16721238 — intervention group
Group type: EXPERIMENTAL
Intervention: Russell‐Taylor Recon Nail
Number of subjects: 34
Study 16721238 — intervention group
Group type: COMPARATOR
Intervention: Howmedica Long Gamma Nail
Number of subjects: 34
Study 16721238 — intervention group
Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 34
Study 14687248 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 875 mg plus clavulanic acid 125 mg b.i.d., clarithromycin 500 mg b.i.d., omeprazole 20 mg b.i.d. (ACCO)
Number of subjects: 60
Study 11572293 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyract
Number of subjects: 46
Study 11572293 — intervention group
Group type: COMPARATOR
Intervention: Fuji II LC
Number of subjects: 46
Study 9562690 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel adjuvant system (SBAS4) combined with recombinant hepatitis B surface antigen (HBsAg)
Number of subjects: 27
Study 9562690 — intervention group
Group type: COMPARATOR
Intervention: Engerix-B (commercial vaccine)
Number of subjects: 27
Study 8172748 — intervention group
Group type: EXPERIMENTAL
Intervention: Iotrolan
Number of subjects: 238
Study 8172748 — intervention group
Group type: COMPARATOR
Intervention: Iohexol
Number of subjects: 238
Study 2738328 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan (2 gr single dose during operation)
Number of subjects: 110
Study 2738328 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 110
Study 4418439 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal position
Number of subjects: 0
Study 4418439 — intervention group
Group type: COMPARATOR
Intervention: Left tilt position
Number of subjects: 0
Study 30587296 — intervention group
Group type: EXPERIMENTAL
Intervention: Pay-it-forward group
Number of subjects: 408
Study 30587296 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care group
Number of subjects: 408
Study 28789465 — intervention group
Group type: EXPERIMENTAL
Intervention: McKenzie method‐based self‐management approach
Number of subjects: 396
Study 28789465 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention control group
Number of subjects: 396
Study 24451612 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturopathic approach to CVD prevention (NC+EUC)
Number of subjects: 0
Study 24451612 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC; usual care plus biometric screening)
Number of subjects: 0
Study 23029946 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupirtine maleate 100 mg thrice daily
Number of subjects: 104
Study 23029946 — intervention group
Group type: COMPARATOR
Intervention: Tramadol hydrochloride 50 mg thrice daily
Number of subjects: 104
Study 20491044 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of bevacizumab (1.25 mg) 48 hours before surgery
Number of subjects: 40
Study 20491044 — intervention group
Group type: COMPARATOR
Intervention: No intravitreal injection (control group)
Number of subjects: 40
Study 18586222 — intervention group
Group type: EXPERIMENTAL
Intervention: Center-based exercise program (n=11)
Number of subjects: 23
Study 18586222 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program (n=12)
Number of subjects: 23
Study 16082697 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg nebulized albuterol
Number of subjects: 65
Study 16082697 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg nebulized racemic epinephrine
Number of subjects: 65
Study 16082697 — intervention group
Group type: COMPARATOR
Intervention: Nebulized saline placebo
Number of subjects: 65
Study 11818179 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling plus behavioral intervention (electronic television time manager)
Number of subjects: 28
Study 11818179 — intervention group
Group type: COMPARATOR
Intervention: Counseling alone
Number of subjects: 28
Study 10402146 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling attendance and opiate abstinence (week 2)
Number of subjects: 59
Study 10402146 — intervention group
Group type: EXPERIMENTAL
Intervention: Opiate-negative urine samples and counseling attendance (week 2)
Number of subjects: 59
Study 10402146 — intervention group
Group type: EXPERIMENTAL
Intervention: Submitting two opiate negative urine samples and attending two counseling sessions (week 2)
Number of subjects: 59
Study 10402146 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment response (week 2)
Number of subjects: 59
Study 7473480 — intervention group
Group type: EXPERIMENTAL
Intervention: Low impact fitness training
Number of subjects: 73
Study 7473480 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback
Number of subjects: 73
Study 7473480 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 73
Study 2304505 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose of Edmonston-Zagreb vaccine
Number of subjects: 1061
Study 2304505 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium dose of Edmonston-Zagreb vaccine
Number of subjects: 1061
Study 2304505 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of Edmonston-Zagreb vaccine
Number of subjects: 1061
Study 2304505 — intervention group
Group type: COMPARATOR
Intervention: Standard dose of Schwarz vaccine
Number of subjects: 1061
Study 2304505 — intervention group
Group type: COMPARATOR
Intervention: Medium dose of Schwarz vaccine
Number of subjects: 1061
Study 2304505 — intervention group
Group type: COMPARATOR
Intervention: High dose of Schwarz vaccine
Number of subjects: 1061
Study 2304505 — intervention group
Group type: COMPARATOR
Intervention: Standard dose of Schwarz vaccine in nine-month-olds
Number of subjects: 1061
Study 7202858 — intervention group
Group type: EXPERIMENTAL
Intervention: Myo-inositol tablets
Number of subjects: 9
Study 7202858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31412825 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher income (quartiles)
Number of subjects: 740
Study 31412825 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher relative financial contribution to the household (more than partner)
Number of subjects: 740
Study 31412825 — intervention group
Group type: EXPERIMENTAL
Intervention: Contributing more than partner
Number of subjects: 740
Study 28495343 — intervention group
Group type: EXPERIMENTAL
Intervention: Video group
Number of subjects: 191
Study 28495343 — intervention group
Group type: EXPERIMENTAL
Intervention: Picture group
Number of subjects: 191
Study 28495343 — intervention group
Group type: COMPARATOR
Intervention: Control group (verbal group)
Number of subjects: 191
Study 26375471 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise program
Number of subjects: 50
Study 24252125 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice-level intervention (multifaceted, evidence-based, tailored intervention with a Practice Facilitator)
Number of subjects: 789
Study 24252125 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-level intervention (one-hour visit with a Prevention Practitioner providing a tailored 'prevention prescription')
Number of subjects: 789
Study 24252125 — intervention group
Group type: EXPERIMENTAL
Intervention: Both practice- and patient-level interventions
Number of subjects: 789
Study 24252125 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 789
Study 21234672 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg daily)
Number of subjects: 181
Study 21234672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 19250820 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-radiation ('maintenance') chemotherapy
Number of subjects: 280
Study 19250820 — intervention group
Group type: COMPARATOR
Intervention: Pre-radiation ('sandwich') chemotherapy
Number of subjects: 280
Study 17503220 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive-expressive group therapy (SEGT)
Number of subjects: 0
Study 17503220 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 16939031 — intervention group
Group type: COMPARATOR
Intervention: Acid/Transbond XT
Number of subjects: 3
Study 16939031 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid/APC Plus
Number of subjects: 3
Study 16939031 — intervention group
Group type: EXPERIMENTAL
Intervention: TSEP/APC Plus
Number of subjects: 3
Study 14756454 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling method B (higher water bolus temperature with extensive head/chest cooling)
Number of subjects: 23
Study 14756454 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling method B
Number of subjects: 23
Study 14756454 — intervention group
Group type: COMPARATOR
Intervention: Cooling method A (lower water temperature)
Number of subjects: 23
Study 10367612 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood states (mellow, anxious/annoyed, elated/happy, disengaged/sleepy)
Number of subjects: 154
Study 9304933 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflation pressure of 4.0-6.6 kPa
Number of subjects: 52
Study 9304933 — intervention group
Group type: COMPARATOR
Intervention: Traditionally used pressure of 33.3-40.0 kPa
Number of subjects: 52
Study 1801560 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous gamma-globulin (IVGG) at doses of 200 or 400 mg/kg X 5
Number of subjects: 0
Study 1801560 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (ASA)
Number of subjects: 0
Study 1801560 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous gamma-globulin (IVGG)
Number of subjects: 0
Study 6218776 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial acupuncture
Number of subjects: 17
Study 6218776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 31395096 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic exercise training (HIGH-INT)
Number of subjects: 60
Study 31395096 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise training (MOD-INT)
Number of subjects: 60
Study 31395096 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control group (CON)
Number of subjects: 60
Study 28558833 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide (AB) 400 μg/formoterol fumarate (FF) 12 μg
Number of subjects: 0
Study 26381519 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous rhAPC (24 µg·kg(‐1)·h(‐1))
Number of subjects: 24
Study 26381519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 23085041 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-week behavioral treatment
Number of subjects: 69
Study 21501494 — intervention group
Group type: EXPERIMENTAL
Intervention: L-lysine (6 g/day)
Number of subjects: 10
Study 21501494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 19339794 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 30
Study 19339794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 16931891 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab treatment
Number of subjects: 0
Study 16931891 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 15264973 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus control
Number of subjects: 0
Study 15264973 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcement
Number of subjects: 0
Study 11744565 — intervention group
Group type: EXPERIMENTAL
Intervention: Postal questionnaire
Number of subjects: 32990
Study 11744565 — intervention group
Group type: EXPERIMENTAL
Intervention: Interview by lay interviewer
Number of subjects: 32990
Study 11744565 — intervention group
Group type: EXPERIMENTAL
Intervention: Interview by nurse
Number of subjects: 32990
Study 11744565 — intervention group
Group type: COMPARATOR
Intervention: Control (interview methods combined)
Number of subjects: 32990
Study 9017772 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime (400 mg)
Number of subjects: 0
Study 9017772 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten (400 mg)
Number of subjects: 0
Study 9017772 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (500 mg)
Number of subjects: 0
Study 9017772 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor (500 mg)
Number of subjects: 0
Study 8318323 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthetic infiltration prior to cannulation
Number of subjects: 40
Study 8318323 — intervention group
Group type: COMPARATOR
Intervention: No local anaesthetic infiltration
Number of subjects: 40
Study 3531311 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg b.i.d. plus aspirin 650 mg q.i.d.
Number of subjects: 40
Study 3531311 — intervention group
Group type: COMPARATOR
Intervention: Placebo b.i.d. plus aspirin 650 mg q.i.d.
Number of subjects: 40
Study 29572600 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 12
Study 29572600 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 12
Study 28481230 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g isomaltulose in 400 mL of water
Number of subjects: 15
Study 28481230 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g isomaltulose in 400 mL of green tea
Number of subjects: 15
Study 28481230 — intervention group
Group type: COMPARATOR
Intervention: 50 g sucrose in 400 mL of water
Number of subjects: 15
Study 28481230 — intervention group
Group type: COMPARATOR
Intervention: Green tea with sucrose
Number of subjects: 15
Study 28481230 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea with isomaltulose
Number of subjects: 15